SAB Biotherapeutics, Inc. (SABSW)

SAB Biotherapeutics is a biopharmaceutical company with an unusual origin story and a novel manufacturing approach to creating human antibody therapies. The company was founded to develop and commercialise a platform technology that uses genetically modified cattle to produce human polyclonal antibodies—a manufacturing method that differs fundamentally from the dominant monoclonal-antibody paradigm that has dominated therapeutic antibody development for decades. SAB is now in transition from a pre-clinical technology-validation phase toward clinical development of multiple programs, a shift that will test whether its transgenic-cattle platform can deliver therapeutic antibodies with advantages over conventional methods.

The founding vision: cattle as bioreactors

SAB Biotherapeutics was founded in 2002 by scientists who recognised that antibodies—the immune system’s precision weapons against pathogens and cancer cells—could be produced more efficiently using genetically modified animals than using conventional cell-culture techniques. The idea is decades old but had remained impractical until advances in molecular biology made it feasible.

The company developed a proprietary technology to genetically engineer cattle such that their bodies produce human antibodies in their blood serum. When vaccinated or exposed to an antigen (a foreign molecule or pathogen), the transgenic cattle mount an immune response and produce a diverse collection of human antibodies tailored to that antigen. SAB harvests the antibodies from the cattle’s blood and purifies them for therapeutic use.

This approach has conceptual advantages over the dominant monoclonal-antibody (mAb) technology. Monoclonal antibodies are single, uniform antibodies derived from a single clone of immune cells, and they are the gold standard in modern therapeutics—tens of billions of dollars of pharmaceutical revenue flows from monoclonal-antibody drugs. However, they are expensive to develop and manufacture. A polyclonal antibody cocktail—a mixture of many different antibodies, all targeting the same antigen from different angles—can sometimes be more effective than a single monoclonal and may be cheaper and faster to produce.

Technology and platform mechanics

SAB’s transgenic cattle produce human antibodies because their genome has been modified to contain human antibody genes. When the cattle’s immune system is activated—through vaccination or experimental immunisation with a specific antigen—their B cells generate a diverse repertoire of antibodies against that target, all of them human.

The company collects blood from vaccinated cattle, isolates the antibody-rich serum, and purifies the specific antibodies of interest. The approach yields a polyclonal antibody product: a mixture of antibodies with different specificities against the same target, but all derived from the same animal and therefore consistent from batch to batch (unlike earlier polyclonal products derived from animals, which were inherently variable).

The platform claims several potential advantages: faster development timelines than monoclonal-antibody technology (which requires cell-line development and screening), potentially lower manufacturing costs (blood collection is cheaper than cell culture), and the possibility that a polyclonal mixture might be clinically superior to a single monoclonal by attacking the same target from multiple angles.

Pre-clinical validation and early partnerships

SAB spent its first decade and a half validating the technology and demonstrating that antibodies produced in transgenic cattle were capable of entering clinical development. The company conducted pre-clinical studies showing that its polyclonal antibodies could neutralise infectious agents and modulate immune responses in animal models.

During this period SAB entered partnerships with major pharmaceutical companies and government agencies to develop antibodies targeting infectious diseases and other therapeutic areas. Partnerships with companies like GlaxoSmithKline, Boehringer Ingelheim, and government agencies provided both validation of the technology and important funding to support pre-clinical and early clinical development.

The company also built out manufacturing capability, though scaling a transgenic-cattle operation to produce clinical and eventually commercial quantities of purified antibodies presented unique logistical and regulatory challenges. Cattle development and husbandry require years of lead time; unlike cell-culture manufacturing, which can be expanded by building new bioreactors, expanding cattle-based antibody production requires breeding and maintaining larger herds.

Early clinical programs and the shift to independent development

By the late 2010s, SAB had advanced multiple antibody programs toward clinical trials and was evaluating which programs to prioritise for internal development versus partnerships. The company went public in 2019 (through a merger with a special-purpose acquisition company, a common route for early-stage biotech) to raise capital for clinical development and manufacturing scale-up.

Current and recent programs include antibody therapies targeting infectious diseases like COVID-19 and influenza, as well as cancer immunotherapy applications. The specifics of clinical progress vary by program, but the essential transition underway is from pure technology validation toward therapeutic development—a shift that requires substantially larger capital investment, longer timelines, and regulatory navigation.

Manufacturing scale and regulatory pathway

A central question for SAB’s future is whether regulatory agencies (the FDA in the United States and comparable bodies elsewhere) will accept polyclonal antibody products as therapeutic drugs. The regulatory framework for therapeutics was built around pure chemical drugs and monoclonal antibodies; polyclonal antibodies represent a newer paradigm. Regulatory guidance for polyclonal antibody therapeutics is less mature than for monoclonals, creating uncertainty about what characterisation and testing will be required to support drug approvals.

Manufacturing at scale adds another layer of complexity. The company must demonstrate that it can produce consistent batches of purified antibodies from its cattle herd; that the antibodies are safe and pure enough for human use; and that the regulatory agencies reviewing the data will accept the manufacturing process as reliable and reproducible.

The competitive and market landscape

The therapeutic antibody market is enormous and dominated by monoclonal-antibody drugs. SAB is competing to establish a new modality within that market—polyclonal antibodies as an alternative to monoclonals in certain applications. The company faces competition from conventional monoclonal-antibody developers and from other emerging platforms trying to create synthetic polyclonal or polyclonal-like therapies using cell-culture or synthetic-biology methods.

The value proposition for polyclonal antibodies is strongest in infectious disease (where a mixture of antibodies might be more effective than a single monoclonal at neutralising variants) and potentially in some cancer immunotherapy applications. Whether the clinical and regulatory reality bears that out depends on the results of ongoing trials.

Strategic positioning and near-term milestones

SAB’s path forward depends on achieving several critical milestones: advancing one or more programs into Phase 2 clinical trials (demonstrating preliminary efficacy and safety); obtaining regulatory clarity on the manufacturing and approval pathway for polyclonal-antibody therapeutics; and managing capital carefully while building manufacturing capacity.

The company has stated a goal of reducing its cash burn and achieving profitability, but as an early-stage biopharmaceutical company, it is not currently profitable and will require additional capital before any program is likely to generate revenue.

How to research SAB Biotherapeutics as an investment

Investors examining SAB should begin with the company’s SEC filings (CIK 0001833214), which detail the company’s financial position, pipeline programs, and manufacturing capabilities. The quarterly earnings reports and investor presentations offer updates on clinical progress and partnership discussions.

Key metrics to monitor: the advancement of clinical programs (which trials are enrolling, what efficacy signals emerge), the company’s cash runway and capital-raise activity, the regulatory feedback on manufacturing and approval pathways, and any partnerships or licensing agreements that suggest third-party confidence in the platform.

Readers should also track the broader therapeutic-antibody market and any published clinical data from competing polyclonal-antibody programs, to assess whether the polyclonal approach is gaining traction relative to conventional monoclonal antibodies. For early-stage biotech, the science and the regulatory pathway matter as much as the financials.